[Multicenter clinical trial of the antitumor drug Dioxadet (phase II)].
A stage II of the joint clinical study of Dioxadet, an ethylene imine drug, was carried out to evaluate its therapeutic effect in 229 patients and side-effects in 239 patients with malignancies of various sites. Marked therapeutic effect was observed in ascitic malignancies of the ovary and a moderate one--in disseminated breast cancer. The most frequent side-effect was reversible myelodepression, often delayed.
Gershanovich
M L
ML
Prof. N.N. Petrov Research Institute of Oncology, Ministry of Health of the RF, St. Petersburg.
Filov
V A
VA
Kotova
D G
DG
Stukov
A N
AN
Sokolov
Iu N
IuN
Ivin
B A
BA
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome; D014227:Triazines / Q000009:adverse effects / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D014227:Triazines; C040269:dioxadet
Rezul'taty kooperirovannogo klinicheskogo izucheniia protivoopukholevogo preparata dioksadèt po II faze.